Urinary excretion of protectin (CD59), complement SC5b-9 and cytokines in membranous glomerulonephritis.
Protectin (CD59) is a low molecular weight glycophosphoinositol-anchored inhibitor of the membrane attack complex of complement (MAC) that is present, for example, on the membranes of endothelial cells and on epithelial cells of glomeruli and distal tubuli. To examine for the possibility that CD59 becomes detached from cell surfaces following cell injury, this study evaluated renal excretion of CD59 in patients with idiopathic membranous glomerulonephritis (MGN; N = 21), diabetic nephropathy (DNP; N = 15) and in healthy control subjects (N = 13). CD59 in human urine was quantitated by a competitive solid-phase radioimmunoassay having approximately 13 kDa soluble urinary CD59 as a standard. Immunofluorescence microscopy demonstrated a decreased expression of CD59 in the glomeruli of MGN patients. Using a Triton X-114 phase separation method 91 to 97% of urinary CD59 was found to be in a soluble form without anchor-associated phospholipid. The mean (+/- SEM) level of urinary CD59 was 5.6 +/- 0.2 micrograms/ml in MGN patients, 3.7 +/- 0.4 micrograms/ml in healthy controls (P < 0.001) and 2.6 +/- 0.1 in DNP patients (P < 0.001). When related to urinary creatinine (UCr) the corresponding values were 11.9 +/- 5.6, 4.8 +/- 0.3 (P = 0.021) and 4.4 +/- 0.2 (P < 0.002), respectively. The amount of CD59 in urine correlated with the urinary excretion of soluble terminal complement complexes, SC5b-9 (r = 0.594, P < 0.006) in MGN patients. The excretion of CD59 also correlated with the excretion of the inflammatory mediator IL-1 beta (r = 0.671, P = 0.001) but not with TNF-alpha (r = 0.314, P = 0.178). No correlation of CD59 excretion was observed with duration of the disease level of proteinuria, serum albumin concentration or serum creatinine level. Based on these findings we speculate that the increased excretion of CD59 into urine in MGN patients is due to complement activation and inflammation induced shedding of CD59 from glomerular cells.
Lehto
T
T
Department of Bacteriology and Immunology, University of Helsinki, Finland.
Honkanen
E
E
Teppo
A M
AM
Meri
S
S
D000328:Adult; D000704:Analysis of Variance; D015703:Antigens, CD / Q000652:urine*; D018957:CD59 Antigens; D015938:Complement Membrane Attack Complex; D003165:Complement System Proteins / Q000652:urine*; D016207:Cytokines / Q000652:urine*; D018450:Disease Progression; D005500:Follow-Up Studies; D015433:Glomerulonephritis, Membranous / Q000652:urine*; D006023:Glycoproteins / Q000652:urine*; D006801:Humans; D007668:Kidney / Q000378:metabolism; D008562:Membrane Glycoproteins / Q000652:urine*; D008856:Microscopy, Fluorescence; D008875:Middle Aged; D011863:Radioimmunoassay
D015703:Antigens, CD; D018957:CD59 Antigens; D015938:Complement Membrane Attack Complex; D016207:Cytokines; D006023:Glycoproteins; D008562:Membrane Glycoproteins; C047610:SC5b-9 protein complex; D003165:Complement System Proteins